Cocktail approach for assessing CYP450 drug-drug interaction liabilities

Latest Press Release

ANA Therapeutics and Quotient Sciences Announce Partnership to Manufacture Niclosamide Drug Candidate as a Potential Treatment for COVID-19

You are about to download this document, please enter your contact details below to start downloading.

Scientific Posters

Cocktail approach for assessing CYP450 drug-drug interaction liabilities - ISSX 2017

This poster explains the cocktail approach for assessing CYP450 drug-drug interaction liabilities including assessment of differential inhibition of liver and gut CYP3A4.

First name

Last name

Company name

Job title

City

Country

Your email

Phone number

Would you like to receive further scientific content including case studies, whitepapers and seminar and webinar invitations?

Yes, please keep me informed
No, please opt me out of further communications

You can find out how we handle your personal information in our privacy policy here.

Ask us a question

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.